Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer

M. Lopez, M. Natali, L. Di Lauro, P. Vici, F. Pignatti, S. Carpano

Research output: Contribution to journalArticle

Abstract

Background. Male breast cancer (MBC) is considered an androgen-dependent tumor, and as in prostatic cancer, responses have been reported with use of antiandrogens or gonadotropin-releasing hormone analogs. Thus, it is reasonable to postulate that better results could be achieved by combining these two agents. Methods. Eleven men with recurrent or progressive carcinoma of the breast have been treated with buserelin 1500 μg subcutaneously daily in the first week and 600 μg daily subsequently and cyproterone acetate (CPA) 100 mg twice a day orally starting 24 hours before the first dose of buserelin. Results. Objective responses have been observed in seven patients with a median duration of 11.5 months (range, 9-24+ months). Responses were not correlated to the dominant site of disease. Three patients had stable disease lasting 5 months. Median survival was 18.5 months. Side effects primarily were decrease or loss of libido, impotence, and hot flushes. Conclusions. Total androgen blockade with buserelin and CPA seems effective in the treatment of patients with advanced cancer of the male breast, but its superiority over standard androgen suppression remains to be demonstrated.

Original languageEnglish
Pages (from-to)502-505
Number of pages4
JournalCancer
Volume72
Issue number2
Publication statusPublished - 1993

Keywords

  • buserelin
  • cyproterone acetate
  • hormonal treatment
  • male breast cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Lopez, M., Natali, M., Di Lauro, L., Vici, P., Pignatti, F., & Carpano, S. (1993). Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer. Cancer, 72(2), 502-505.